HOUSTON, Mar 24, 2010 -- Management of Emerging Healthcare Solutions, Inc. (PINKSHEETS: EHSI) expects to reap many benefits from the Biotech industry's new 12-year haven from Biosimilar competition that was included in the healthcare reform legislation passed by the US House of Representatives on Sunday.
Emerging Healthcare Solutions, Inc. closed at $1.37 Tuesday, trading 564,466 shares.
EHSI: Biotech Industry Wins New 12-Year Hedge Against Competition
About Emerging Healthcare Solutions, Inc.
Emerging Healthcare Solutions, Inc. is a company dedicated to providing guidance to participants in the healthcare industry. Our primary goal is to supply a roadmap showing how to realize substantial profits from the changes occurring right now in the healthcare industry. Our common stock is traded under the symbol EHSI.
For more information, visit http://www.emerginghealthcaresolutionsinc.com.
For additional penny stock news, tools and tips visit http://stockprofiler.us/?action=main.market_news
-------------------------------------------
NEW YORK, March 24, 2010 -- Intellect Neurosciences, Inc. (OTCBB: ILNS), a biopharmaceutical company focused on development of disease-modifying therapeutic agents for Alzheimer's disease ("AD"), announced today that its Chairman & Chief Executive Officer, Daniel Chain, PhD, will deliver the key note speech at a session entitled "Alzheimer's Monoclonal Antibodies" at the BIT Life Sciences 2nd International Conference on Monoclonal Antibodies. The conference, known as ICA-2010 (www.bitlifesciences.com/ica2010), is being held March 24 - 26 in Beijing, China.
Intellect Neurosciences, Inc. closed at $0.11 Tuesday, trading 51,688 shares.
Intellect Neurosciences, Inc. Announces CEO to Deliver Key Note Speech on Alzheimer's Monoclonal Antibodies at International Conference in Beijing
About Intellect Neurosciences, Inc.
Intellect Neurosciences, Inc. is a biopharmaceutical company engaged in the discovery and development of disease-modifying therapeutic agents for the treatment and prevention of Alzheimer's disease and other disorders. The Company's drug product pipeline includes OX1 which has been tested in Phase 1 clinical trials; IN-N01, a humanized monoclonal antibody designed to promote the clearance of soluble beta amyloid; and RECALL-VAX, a vaccine technology that has potential to delay or prevent Alzheimer's disease in people who are at risk. The Company has underlying intellectual property assets, including several patent families supporting its internal programs, and a pivotal patent estate regarding passive AD immunotherapy. The Company granted a non-exclusive, worldwide, royalty-bearing license to its ANTISENILIN® monoclonal antibody platform to Wyeth and Elan Pharma International Ltd. The license grants rights to Wyeth and Elan under Intellect's patents with respect to the development and sale of Bapineuzumab, a monoclonal antibody intended to treat AD. Wyeth and Elan are currently testing Bapineuzumab in several thousand Alzheimer's patients in a Phase 3 clinical trial. The Company granted a similar non-exclusive license to another top tier global pharmaceutical company and granted an option to purchase a license to GlaxoSmithKline.
For additional information, please visit http://www.intellectns.com.
For additional penny stock news, tools and tips visit http://stockprofiler.us/?action=main.market_news
-----------------------------------------
StockProfiler.US Announcement!
Membership with access to enhanced stock investing tools is now FREE! Claim yours at http://stockprofiler.us/index.php?action=main.register
Stay connected with StockProfiler.US – Fan up with us on Facebook (keyword: StockProfiler.US) or follow us on Twitter at http://twitter.com/StockProfilerUS
View free penny stock company videos and product reviews at our YouTube channel. Visit http://www.youtube.com/StockProfilerUS
-------------------------------------------
About StockProfiler.US:
StockProfiler.US is a media source for publicly traded penny stock companies and investors to come together and discover market opportunities. Public companies can effectively broadcast their message to a targeted audience who come to StockProfiler.US seeking an advantage by discovering companies in their startup phase or ones who have yet to be discovered by the investment community.
Call us at (603) 424-4420 or email info@stockprofiler.us
-------------------------------------------
Please Note: All news contained herein has been previously issued by the companies mentioned in this release, and is the property of each company, respectively. All news is edited for content. The companies that are discussed in this opinion have not approved the statements made in this opinion.
This opinion contains forward-looking statements that involve risks and uncertainties. This material is for informational purposes only and should not be construed as an offer or solicitation of an offer to buy or sell securities.
Stock Profiler.US, LLC's News Division includes but is not limited to: http://www.stockprofiler.us, http://www.associatesfortune.com, http://www.fastmoneytalk.com, http://www.markettelegraph.com, http://www.thewallstreetleader.com, and http://www.daytradersdigest.com.
Stock Profiler.US, LLC has been compensated for services rendered; Stock Profiler.US, LLC is not a licensed broker, broker dealer, market maker, investment banker, investment advisor, analyst or underwriter.
To view full disclaimers and terms of use, go to http://stockprofiler.us/?action=main.disclaimer
-------------------------------------------
Keywords: penny stock, penny stock news, penny stock alerts, penny stock updates, penny stock news, penny stock profile
Posts
No comments:
Post a Comment